MAG
VVOS icon

Millrace Asset Group’s Vivos Therapeutics VVOS Stock Holding History

Millrace Asset Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,760
Closed -$465K – 81
2021
Q2 		$465K Buy
+3,760
New +$613K 0.24% 81

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIA
Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Millrace Asset Group's VVOS Position: Q3 2021 in Review

Millrace Asset Group sold out of Vivos Therapeutics (VVOS) in Q3 2021, closing a stake of 3,760 shares — an estimated $465K sold.

Millrace Asset Group first reported a position in VVOS in Q2 2021 and held it in 1 quarter. The position peaked at $465K in Q2 2021. 37 funds tracked by Wall St. Rank hold VVOS as of Q3 2021.

  • Millrace Asset Group reported no remaining Vivos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Millrace Asset Group sold 3,760 Vivos Therapeutics shares in Q3 2021, an estimated $465K.
  • Millrace Asset Group first reported a position in Vivos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Millrace Asset Group's Vivos Therapeutics position peaked at $465K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2021.

Based on Millrace Asset Group's 13F filing for Q3 2021, filed 12 Nov 2021.